Department of Internal Medicine, Gachon University School of Medicine, 21 Namdongdae-ro 774-gil, Guwol 1-dong, Namdong-gu, Incheon, 405-760, Republic of Korea.
Ann Hematol. 2012 Dec;91(12):1897-906. doi: 10.1007/s00277-012-1533-z. Epub 2012 Aug 3.
In order to evaluate prognostic value of CD99 expression in patients with diffuse large B-cell lymphoma (DLBCL) who underwent treatment with rituximab-CHOP immunochemotherapy, immunohistochemistry for CD99/CD10/BCL-2/BCL-6/MUM-1 was performed on nodal DLBCL specimens from 70 patients. Patients were classified as either germinal center B-cell (GCB) subtype or non-GCB subtype according to the Muris algorithm. A superior 2-year event-free survival (EFS) was observed in patients with the GCB subgroup, compared to those with the non-GCB subgroup (p = 0.034). The distribution of CD99 expression (29 patients; 41.4 %) did not show deviation according to subtype and was not prognostic for survival in the entire patient population. Among patients with the GCB subgroup, better EFS and overall survival (OS) were observed in CD99+ patients, compared to CD99- patients. Conversely, among patients with the non-GCB subgroup, inferior EFS and OS were reported in CD99+ patients. Superior 2-year EFS (p = 0.004) and 2-year OS (p = 0.003) were observed in patients with GCB/CD99+ and non-GCB/CD99- compared to the others, and the combination classification was found to be an independent prognostic factor.
为了评估接受利妥昔单抗-CHOP 免疫化疗治疗的弥漫性大 B 细胞淋巴瘤 (DLBCL) 患者中 CD99 表达的预后价值，对 70 例 DLBCL 患者的淋巴结标本进行了 CD99/CD10/BCL-2/BCL-6/MUM-1 的免疫组织化学检测。根据 Muris 算法，患者被分为生发中心 B 细胞 (GCB) 亚型或非 GCB 亚型。与非 GCB 亚组相比，GCB 亚组患者的 2 年无事件生存 (EFS) 更高 (p=0.034)。CD99 表达的分布 (29 例;41.4%) 未根据亚型出现偏差，并且在整个患者群体中对生存没有预后意义。在 GCB 亚组中，与 CD99-患者相比，CD99+患者的 EFS 和总生存 (OS) 更好。相反，在非 GCB 亚组中，CD99+患者的 EFS 和 OS 较差。与其他患者相比，GCB/CD99+和非 GCB/CD99-患者的 2 年 EFS (p=0.004) 和 2 年 OS (p=0.003) 更高，并且联合分类被发现是一个独立的预后因素。
